Trials / Completed
CompletedNCT02806648
A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase II trial to assess the activity and safety of PD0332991 in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) with overexpression of cell cycle markers (Cdk4 and/or phospho-Rb1 and/or cyclin D1)
Detailed description
The purpose of this study is to evaluate the activity and safety of PD0332991 in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) with overexpression of cell cycle markers (Cdk4 and/or phospho-Rb1 and/or cyclin D1)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Palbociclib | Palbociclib |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2017-07-01
- Completion
- 2018-01-01
- First posted
- 2016-06-20
- Last updated
- 2018-01-23
Locations
9 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02806648. Inclusion in this directory is not an endorsement.